Search

GSK Position On Access And Benefit Sharing Of Genetic Resources And Related Information September 2023

Media

https://www.gsk.com/media/10531/gsk-position-on-access-and-benefit-sharing-of-genetic-resources-and-related-information-september-2023.pdf

First published: 12 September 2023

GSK Position On Access And Benefit Sharing Of Genetic Resources And Related Information

Media

https://www.gsk.com/media/11829/gsk-position-on-access-and-benefit-sharing-of-genetic-resources-and-related-information.pdf

First published: 19 February 2025

GSK RSV Investor Science Event ID Week 2022

Media

https://www.gsk.com/media/9614/gsk-rsv-investor-science-event-id-week-2022.pdf

First published: 21 October 2022

GSK RSV Investor Science Event ID Week 2022

Media

https://www.gsk.com/media/9617/gsk-rsv-investor-science-event-id-week-2022.pdf

First published: 21 October 2022

Sanofi and GSK confirm agreement with European Union to supply up to 300 million doses of adjuvanted COVID-19 vaccine

Media

This confirmation follows the announcement on 31 July of advanced discussions between the companies and the EC.

https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-confirm-agreement-with-european-union-to-supply-up-to-300-million-doses-of-adjuvanted-covid-19-vaccine/

First published: 18 September 2020

Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate

Media

Over 400 participants being enrolled in Phase 1/2 study.

https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-initiate-phase-12-clinical-trial-of-covid-19-adjuvanted-recombinant-protein-based-vaccine-candidate/

First published: 03 September 2020

Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate

Media

New Phase 2 study assesses potential for refined antigen formulation to achieve optimal immune response, including in older adults.

https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-initiate-new-phase-2-study-of-their-adjuvanted-recombinant-protein-based-covid-19-vaccine-candidate/

First published: 22 February 2021

Medicago and GSK announce start of Phase 2/3 clinical trials of adjuvanted COVID-19 vaccine candidate

Media

Based on the positive Phase 1 results, Medicago has decided to launch the Phase 2/3 clinical trial with GSK’s pandemic adjuvant.

https://www.gsk.com/en-gb/media/press-releases/medicago-and-gsk-announce-start-of-phase-23-clinical-trials-of-adjuvanted-covid-19-vaccine-candidate/

First published: 12 November 2020

Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine programme to improve immune response in the elderly

Media

Phase 1/2 interim results showed an immune response comparable to patients who recovered from COVID-19 in adults aged 18 to 49 years

https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-announce-a-delay-in-their-adjuvanted-recombinant-protein-based-covid-19-vaccine-programme-to-improve-immune-response-in-the-elderly/

First published: 11 December 2020

GSK grants exclusive technology license for clinical-stage Ebola vaccines to Sabin Vaccine Institute

Media

Transfer from GSK and partnership with NIAID will enable Sabin to advance development of the candidate vaccines

https://www.gsk.com/en-gb/media/press-releases/gsk-grants-exclusive-technology-license-for-clinical-stage-ebola-vaccines-to-sabin-vaccine-institute/

First published: 06 August 2019